

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 02 LMEDLINE coverage updated
NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
NEWS 4 JUL 02 CHEMCATS accession numbers revised
NEWS 5 JUL 02 CA/Caplus enhanced with utility model patents from China
NEWS 6 JUL 16 CAplus enhanced with French and German abstracts
NEWS 7 JUL 18 CA/Caplus patent coverage enhanced
NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9 JUL 30 USGENE now available on STN
NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 11 AUG 06 BEILSTEIN updated with new compounds
NEWS 12 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 13 AUG 13 CA/Caplus enhanced with additional kind codes for granted patents
NEWS 14 AUG 20 CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS 15 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 16 AUG 27 USPATOLD now available on STN
NEWS 17 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 18 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 19 SEP 13 FORIS renamed to SOFIS
NEWS 20 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 21 SEP 17 CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS 22 SEP 17 CAplus coverage extended to include traditional medicine patents

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:56:26 ON 21 SEP 2007

=> file caplus medline embase biosis
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'CAPLUS' ENTERED AT 15:56:48 ON 21 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:56:48 ON 21 SEP 2007

FILE 'EMBASE' ENTERED AT 15:56:48 ON 21 SEP 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:56:48 ON 21 SEP 2007
Copyright (c) 2007 The Thomson Corporation

=> s galantamine
L1 4488 GALANTAMINE

=> s attention deficit disorder
L2 32239 ATTENTION DEFICIT DISORDER

=> s L1 and L2
L3 74 L1 AND L2

=> dup rem L3
PROCESSING COMPLETED FOR L3
L4 71 DUP REM L3 (3 DUPLICATES REMOVED)

=> s L4 and (AY<2004 or PY<2004 or PRY<2004)
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
2 FILES SEARCHED...
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
'2004' NOT A VALID FIELD CODE
L5 19 L4 AND (AY<2004 OR PY<2004 OR PRY<2004)

=> d 1-19 L5 ibib abs

L5 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1004355 CAPLUS
DOCUMENT NUMBER: 143:279430
TITLE: Use of D4 and 5-HT2a antagonists, inverse agonists or
partial agonists
INVENTOR(S): Buntinx, Erik
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 126 pp., Cont.-in-part of U.S.
Ser. No. 803,793.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005203130	A1	20050915	US 2004-984683	20041109 <--
US 2005119253	A1	20050602	US 2003-725965	20031202 <--
US 2005119248	A1	20050602	US 2004-752423	20040106 <--
US 2005119249	A1	20050602	US 2004-803793	20040318 <--

EP 1541197 A1 20050615 EP 2004-25035 20041021 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
CA 2547639 A1 20050616 CA 2004-2547639 20041202 <--
WO 2005053796 A1 20050616 WO 2004-BE172 20041202 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG
EP 1708790 A1 20061011 EP 2004-801138 20041202 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU
JP 2007513095 T 20070524 JP 2006-541759 20041202 <--
US 2007078162 A1 20070405 US 2006-580962 20060531 <--
PRIORITY APPLN. INFO.:
US 2003-725965 A2 20031202 <--
EP 2004-447001 A 20040105
US 2004-752423 A2 20040106
US 2004-803793 A2 20040318
EP 2004-25035 A 20041021
CA 2003-2451798 A 20031202 <--
EP 2003-447279 A 20031202 <--
CA 2004-2461248 A 20040318
EP 2004-447066 A 20040318
JP 2004-349085 A 20041104
US 2004-984683 A 20041109
CA 2004-2487529 A 20041115
WO 2004-BE172 W 20041202

AB The present invention relates to the use of compds. and compns. of compds. having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperesthesia-dissociative phenomena-etc.). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compds. having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compds. having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compns. of said compds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biol. compound or in two different chemical and/or biol. compds.

L5 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:516281 CAPLUS
DOCUMENT NUMBER: 143:38421
TITLE: Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
INVENTOR(S): Buntinx, Erik
PATENT ASSIGNEE(S): B&B Beheer N. V., Belg.
SOURCE: Eur. Pat. Appl., 145 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

EP 1541197	A1	20050615	EP 2004-25035	20041021 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
EP 1547650	A1	20050629	EP 2003-447279	20031202 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
EP 1576985	A1	20050921	EP 2004-447066	20040318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
JP 2005194263	A	20050721	JP 2004-349085	20041104 <--
US 2005203130	A1	20050915	US 2004-984683	20041109 <--
CA 2487529	A1	20050602	CA 2004-2487529	20041115 <--
CA 2547639	A1	20050616	CA 2004-2547639	20041202 <--
WO 2005053796	A1	20050616	WO 2004-BE172	20041202 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1708790	A1	20061011	EP 2004-801138	20041202 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
JP 2007513095	T	20070524	JP 2006-541759	20041202 <--
US 2007078162	A1	20070405	US 2006-580962	20060531 <--
PRIORITY APPLN. INFO.:				
			EP 2003-447279	A 20031202 <--
			EP 2004-447001	A 20040105
			EP 2004-447066	A 20040318
			CA 2003-2451798	A 20031202 <--
			US 2003-725965	A2 20031202 <--
			US 2004-752423	A2 20040106
			CA 2004-2461248	A 20040318
			US 2004-803793	A2 20040318
			EP 2004-25035	A 20041021
			JP 2004-349085	A 20041104
			US 2004-984683	A 20041109
			CA 2004-2487529	A 20041115
			WO 2004-BE172	W 20041202

AB The present invention relates to the use of compds. and compns. of compds. having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperesthesia-dissociative phenomena-etc.). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compds. having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compds. having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compns. of said compds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biol. compound or in two different chemical and/or biol. compds.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:395100 CAPLUS
 DOCUMENT NUMBER: 142:435801

TITLE: Pharmaceuticals comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor

INVENTOR(S): Friedl, Thomas; Mierau, Joachim; Raschig, Andreas; Reess, Juergen; Scheel-Krueger, Joergen

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg; Neurosearch A/S

SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039580	A1	20050506	WO 2004-EP11093	20041005 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283425	A1	20050506	AU 2004-283425	20041005 <--
CA 2542442	A1	20050506	CA 2004-2542442	20041005 <--
EP 1675591	A1	20060705	EP 2004-790120	20041005 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1867333	A	20061122	CN 2004-80030623	20041005 <--
JP 2007508336	T	20070405	JP 2006-534638	20041005 <--
US 2005154009	A1	20050714	US 2004-965994	20041015 <--
MX 2006PA03762	A	20060614	MX 2006-PA3762	20060404 <--
IN 2006DN02712	A	20070810	IN 2006-DN2712	20060515 <--
PRIORITY APPLN. INFO.:			EP 2003-23635	A 20031016 <--
			EP 2004-5819	A 20040311
			DE 2003-10353832	A 20031118 <--
			WO 2004-EP11093	W 20041005

OTHER SOURCE(S): MARPAT 142:435801

AB The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a salt, solvate, or a derivative thereof, and at least one acetylcholinesterase inhibitor and a carrier or excipient, and optionally one or more other therapeutic ingredients. Thus, granules contained a monoamine neurotransmitter re-uptake inhibitor 1.585, rivastigmine hydrogen tartrate 9.597, microcryst. cellulose 66.472, dibasic calcium phosphate 66.471, Hypromellose 2.750, crosslinked CM-cellulose sodium 2.000, colloidal silica 0.375, and Mg stearate 0.750 mg/cpsule.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:414630 CAPLUS

DOCUMENT NUMBER: 140:412338

TITLE: Once a day galantamine pharmaceutical compositions and methods of use

INVENTOR(S): Cantillion, Marc; Hsu, Ann; Han, Chien-Hsuan

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004097484	A1	20040520	US 2002-293942	20021114 <--
PRIORITY APPLN. INFO.:			US 2002-293942	20021114 <--

AB Disclosed are once a day pharmaceutical compns. containing acetylcholinesterase inhibitors, including those with nicotinic receptor modulation such as galantamine or a pharmaceutically acceptable salt thereof. Also disclosed is the use of such compns., for example, for treating or preventing cognitive or other CNS performance impairment in a mammal, such as primary or secondary memory impairment, toxic, secondary to medical or psychiatric, Alzheimer's, vascular and other dementias, mild cognitive impairments, and other cognitive impairments, such as attention deficit disorder, fibromyalgia, chronic fatigue syndrome, PTSD and Down's syndrome. This includes behavioral efficacy, as anxiety depression apathy and agitation, in addition to neurophysiol. and functional outcomes including a decrease in care givers distress. A prolonged release tablet contained galantamine HBr 2.16, xanthan gum 19.35, locust bean gum 58.06, microcryst. cellulose (Avicel PH-101) 13.51, lactose monohydrate (Fast-Flo 316) 6.76, and magnesium stearate 0.16%.

L5 ANSWER 5 OF 19 CAPLUS . COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:80456 CAPLUS
DOCUMENT NUMBER: 140:122818
TITLE: Cholinergic therapy for individuals with learning disabilities
INVENTOR(S): Heller, James H.; Kishnani, Priya; Worley, Gordon
PATENT ASSIGNEE(S): Duke University, USA; Spiridigliozzi, Gail A.; Doraiswamy, Murali P.; Krishnan, Ranga R.
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009026	A2	20040129	WO 2003-US22746	20030722 <--
WO 2004009026	A3	20040715		
WO 2004009026	A8	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003256644	A1	20040209	AU 2003-256644	20030722 <--
PRIORITY APPLN. INFO.:			US 2002-397123P	P 20020722 <--
			WO 2003-US22746	W 20030722 <--

AB Cholinergic agents are used to improve specific learning deficits and language function in individuals of normal intelligence. Psychosocial deficits including a pragmatics impairment, reading deficits, a problem solving impairment, an information processing impairment, an adaptive function impairment, social skills impairment, attention impairment, a

mood impairment and employment skills impairment, can also be treated in this manner. The cholinergic treatments can be combined with more traditional educational, psychol., and behavioral therapies for enhanced therapeutic benefit.

L5 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:319255 CAPLUS
 DOCUMENT NUMBER: 138:343854
 TITLE: Buccal sprays or capsules containing drugs for treating disorders of the central nervous system
 INVENTOR(S): Dugger, Harry A., III
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 19
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003077227	A1	20030424	US 2002-230060	20020829 <--
WO 9916417	A1	19990408	WO 1997-US17899	19971001 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 1029536	A1	20000823	EP 2000-109347	19971001 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1036561	A1	20000920	EP 2000-109357	19971001 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2497262	A1	20040429	CA 2003-2497262	20030827 <--
WO 2004035021	A2	20040429	WO 2003-US26847	20030827 <--
WO 2004035021	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003298564	A1	20040504	AU 2003-298564	20030827 <--
EP 1539106	A2	20050615	EP 2003-796314	20030827 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505569	T	20060216	JP 2004-545251	20030827 <--
US 2004141923	A1	20040722	US 2003-671720	20030929 <--
US 2004265239	A1	20041230	US 2003-671715	20030929 <--
US 2005163719	A1	20050728	US 2003-671709	20030929 <--
US 2004120895	A1	20040624	US 2003-726585	20031204 <--
US 6977070	B2	20051220		
US 2005002867	A1	20050106	US 2004-834815	20040427 <--
US 2006159624	A1	20060720	US 2006-384444	20060321 <--
US 2006171896	A1	20060803	US 2006-391297	20060329 <--
US 2006222597	A1	20061005	US 2006-442137	20060530 <--

US 2006216240	A1	20060928	US 2006-443253	20060531 <--
US 2006216241	A1	20060928	US 2006-443254	20060531 <--
PRIORITY APPLN. INFO.:			WO 1997-US17899	A2 19971001 <--
			US 2000-537118	A2 20000329 <--
			EP 1997-911621	A3 19971001 <--
			US 2002-230060	A 20020829 <--
			WO 2003-US26847	W 20030827 <--
			US 2003-671709	A3 20030929 <--
			US 2003-671715	A3 20030929 <--
			US 2003-671720	A3 20030929 <--
			US 2004-834815	A3 20040427

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a lingual spray contained sumatriptan succinate 10-15, EtOH 10-20, propylene glycol 10-15, PEG 35-40, water 10-15, and flavors 2-3%.

L5 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:133030 CAPLUS
 DOCUMENT NUMBER: 138:163577
 TITLE: Improving neurological functions
 INVENTOR(S): Chez, Michael G.
 PATENT ASSIGNEE(S): Carn-Aware LLC, USA
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003013514	A1	20030220	WO 2002-US22341	20020715 <--
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
AU 2002355388	A1	20030224	AU 2002-355388	20020715 <--
US 2006052428	A1	20060309	US 2005-486077	20050210 <--
PRIORITY APPLN. INFO.:			US 2001-310710P	P 20010808 <--
			US 2001-325136P	P 20010927 <--
			WO 2002-US22341	W 20020715 <--

OTHER SOURCE(S): MARPAT 138:163577


AB The present invention relates to materials and methods for treating neurol. diseases and disorders including but not limited to epilepsy and autism, as well as general cognitive problems. Preferred compds. include carnosine and homocarnosine and N-acetyl, methylated (anserine, ophidine), decarboxylated (carcinine) and tauryl derivs. of carnosine and homocarnosine.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:314758 CAPLUS
 DOCUMENT NUMBER: 136:319416
 TITLE: Combination of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders
 INVENTOR(S): Villalobos, Anabella; Cassella, James Vincent; Rajachandran, Lavanya
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Neurogen Corporation
 SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032412	A2	20020425	WO 2001-IB1934	20011015 <--
WO 2002032412	A3	20030320		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002151591	A1	20021017	US 2001-976347	20011012 <--
CA 2426120	A1	20020425	CA 2001-2426120	20011015 <--
AU 2001094117	A5	20020429	AU 2001-94117	20011015 <--
EP 1328294	A2	20030723	EP 2001-974604	20011015 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200302476	A2	20031128	HU 2003-2476	20011015 <--
JP 2004511512	T	20040415	JP 2002-535650	20011015 <--
NZ 525103	A	20041224	NZ 2001-525103	20011015 <--
ZA 2003002918	A	20040413	ZA 2003-2918	20030411 <--
US 2005009861	A1	20050113	US 2004-912993	20040806 <--
PRIORITY APPLN. INFO.:				
			US 2000-241145P	P 20001017 <--
			US 2001-976347	A1 20011012 <--
			WO 2001-IB1934	W 20011015 <--
OTHER SOURCE(S): MARPAT 136:319416				
GI				



I

AB This invention provides a composition for treating a cognitive disorder, which comprises an acetylcholinesterase, and a GABAA inverse agonist selected from a compound (I, where X = e.g., H, halo, Ph, naphthyl, pyridinyl; Y = e.g., C1-8 alkyl, carbocycle). Thus, aricept and a GABAA inverse agonist (e.g., N-benzyl-6-ethoxy-4-oxo-1,4-tetrahydro-1,5-naphthyridine-3-carboxamide), when coadministered, interact to attenuate scopolamine-induced deficits in the spatial water maze.

L5 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:564797 CAPLUS
DOCUMENT NUMBER: 135:117204
TITLE: Computer-based cognitive function testing for
measuring pharmaceutical-related cognitive impairment
INVENTOR(S): Erlanger, David; Kaplan, Darin; Shchogolev, Vladislav;
Theodoracopulos, Alexis; Yee, Philip; Comrie, McDonald
PATENT ASSIGNEE(S): Panmedix Incorporated, USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001054650	A2	20010802	WO 2001-US2187	20010123 <--
W: AU, CA, CH, CZ, IL, JP, KR, SG				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001029717	A5	20010807	AU 2001-29717	20010123 <--
PRIORITY APPLN. INFO.:			US 2000-494476	A 20000131 <--
			WO 2001-US2187	W 20010123 <--

AB The invention generally involves using a computer to show a patient taking a pharmaceutical product a series of cognitive dysfunction tests, receiving the patient's test responses, and analyzing the responses to assess cognitive dysfunction in the patient, whereby a conclusion can be obtained regarding whether symptoms of cognitive dysfunction probably exist or are absent in the patient, and the drug's likely causal effect on cognitive dysfunction. The invention enables the comparison of multiple test results over time.

L5 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:456886 CAPLUS
DOCUMENT NUMBER: 133:94514
TITLE: Controlled release galantamine compositions
for treating Alzheimer's dementia
INVENTOR(S): McGee, John Paul; Gilis, Paul Marie Victor; De Weer,
Marc Maurice Germain; De Conde, Valentin Florent
Victor; De Bruijn, Herman Johannes Catherina; Van
Dycke, Frederic Anne Rodolf
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038686	A1	20000706	WO 1999-EP10257	19991220 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2358062	A1	20000706	CA 1999-2358062	19991220 <--
CA 2358062	C	20061219		
BR 9916835	A	20010925	BR 1999-16835	19991220 <--

EP 1140105	A1	20011010	EP 1999-965527	19991220 <--
EP 1140105	B1	20031022		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101822	T2	20011121	TR 2001-200101822	19991220 <--
HU 200104778	A2	20020429	HU 2001-4778	19991220 <--
JP 2002533396	T	20021008	JP 2000-590639	19991220 <--
EE 200100319	A	20021015	EE 2001-319	19991220 <--
NZ 511643	A	20030725	NZ 1999-511643	19991220 <--
AT 252386	T	20031115	AT 1999-965527	19991220 <--
PT 1140105	T	20040331	PT 1999-965527	19991220 <--
ES 2211215	T3	20040701	ES 1999-965527	19991220 <--
AU 775914	B2	20040819	AU 2000-21006	19991220 <--
TW 262079	B	20060921	TW 1999-88122698	19991223 <--
IN 2001MN00558	A	20050304	IN 2001-MN558	20010515 <--
BG 105564	A	20020131	BG 2001-105564	20010605 <--
NO 2001002857	A	20010608	NO 2001-2857	20010608 <--
HR 2001000463	A1	20020831	HR 2001-463	20010619 <--
ZA 2001005132	A	20020621	ZA 2001-5132	20010621 <--
MX 2001PA06529	A	20010910	MX 2001-PA6529	20010622 <--
US 7160559	B1	20070109	US 2001-868991	20010726 <--
US 2006062856	A1	20060323	US 2005-262668	20051031 <--
US 2006093671	A1	20060504	US 2005-304128	20051215 <--
PRIORITY APPLN. INFO.:			EP 1998-204447	A 19981224 <--
			WO 1999-EP10257	W 19991220 <--
			US 2001-868991	A1 20010726 <--

AB The present invention is concerned with controlled release compns. for oral administration comprising galantamine; and with processes of preparing such controlled release compns. A method of treating Alzheimer's dementia and related dementias comprises administering the controlled release galantamine formulation.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:130564 CAPLUS

DOCUMENT NUMBER: 130:187195

TITLE: Use of cholinesterase inhibitors for treating attention deficit disorders

INVENTOR(S): Snorrason, Ernir; Murray, James Robert

PATENT ASSIGNEE(S): Shire International Licensing B.V., Neth.

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9907359	A1	19990218	WO 1998-GB2378	19980807 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2300405	A1	19990218	CA 1998-2300405	19980807 <--
AU 9887367	A	19990301	AU 1998-87367	19980807 <--
ZA 9807140	A	19990309	ZA 1998-7140	19980807 <--
EP 1001761	A1	20000524	EP 1998-938759	19980807 <--
EP 1001761	B1	20040728		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI					
JP 2001513496	T	20010904	JP 2000-506951	19980807	<--
AT 271865	T	20040815	AT 1998-938759	19980807	<--
ES 2224421	T3	20050301	ES 1998-938759	19980807	<--
TW 577742	B	20040301	TW 1998-87113353	19980813	<--
PRIORITY APPLN. INFO.:			GB 1997-16879	A	19970808 <--
			WO 1998-GB2378	W	19980807 <--

OTHER SOURCE(S): MARPAT 130:187195

AB The invention provides the use of cholinesterase inhibitors, particularly acetylcholinesterase inhibitors such as galanthamine, in the manufacture of a medicament for combating attention deficit disorders.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 19 MEDLINE on STN

ACCESSION NUMBER: 2003133599 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12647432

TITLE: [Acetylcholinesterase inhibitors--beyond Alzheimer's disease].
Inhibitory acetylocholinesterazy--nie tylko w chorobie Alzheimera.

AUTHOR: Kloszewska Iwona

CORPORATE SOURCE: I Klinika Psychiatryczna Katedry Psychiatrii AM w Lodzi.

SOURCE: Psychiatria polska, (2002 Nov-Dec) Vol. 36, No. 6

Suppl, pp. 133-41. Ref: 37

Journal code: 0103314. ISSN: 0033-2674.

PUB. COUNTRY: Poland

DOCUMENT TYPE: (ENGLISH ABSTRACT)

Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LANGUAGE: Polish

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200306

ENTRY DATE: Entered STN: 22 Mar 2003

Last Updated on STN: 6 Jun 2003

Entered Medline: 5 Jun 2003

AB Based on a literature review, the application of Acetylcholinesterase inhibitors, IAChE (donepezil, rivastigmine, galantamine) in the treatment of various illnesses which have cholinergic system disability and dementia in their course--(dementia with Lewy bodies, vascular dementia, Parkinson's disease, Multiple Sclerosis, Down Syndrome), delirium symptoms (e.g. Korsakoff psychosis), hyperkinesia, attention and memory disorders--is presented. Promising results in the treatment of late dyskinesias, in schizophrenia with impaired cognitive function, as well as in the additional treatment of various psychotic states are noted. It should be stressed that in Poland, the IAChE have been approved only in the treatment of slight to moderate dementia in the course of Alzheimer's disease.

L5 ANSWER 13 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004151029 EMBASE

TITLE: 2003 Psychotropic Dosing and Monitoring Guidelines.

AUTHOR: DeBattista C.; Schatzberg A.F.; Norris K.T.

SOURCE: Primary Psychiatry, (2003) Vol. 10, No. 7, pp. 80-84+87-96.

Refs: 75

ISSN: 1082-6319 CODEN: PPRSC5

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 032 Psychiatry

037 Drug Literature Index

038 Adverse Reactions Titles

LANGUAGE: English

ENTRY DATE: Entered STN: 22 Apr 2004
Last Updated on STN: 22 Apr 2004

L5 ANSWER 14 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003041424 EMBASE
TITLE: XIVth World Congress of Pharmacology, San Francisco, CA, USA July 7-12, 2002 new drugs for the treatment of central nervous system disorders.
AUTHOR: Scriabine A.
CORPORATE SOURCE: A. Scriabine, Dept. of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, United States. alexander.scriabine@snet.net
SOURCE: CNS Drug Reviews, (2002) Vol. 8, No. 4, pp. 427-437. .
ISSN: 1080-563X CODEN: CDREFB
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 008 Neurology and Neurosurgery
032 Psychiatry
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 7 Feb 2003
Last Updated on STN: 7 Feb 2003

L5 ANSWER 15 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002420945 EMBASE
TITLE: Alzheimer's disease and the basal forebrain cholinergic system: Relations to β -amyloid peptides, cognition, and treatment strategies.
AUTHOR: Auld D.S.; Kornecook T.J.; Bastianetto S.; Quirion R.
CORPORATE SOURCE: R. Quirion, Douglas Hospital Research Centre, 6875 Blvd. Lasalle, Verdun, Que. H4H IR3, Canada.
quirem@douglas.mcgill.ca
SOURCE: Progress in Neurobiology, (2002) Vol. 68, No. 3, pp. 209-245. .
Refs: 504
ISSN: 0301-0082 CODEN: PGNBA5
PUBLISHER IDENT.: S 0301-0082(02)00079-5
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 008 Neurology and Neurosurgery
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 12 Dec 2002
Last Updated on STN: 12 Dec 2002

AB Alzheimer's disease (AD) is the most common form of degenerative dementia and is characterized by progressive impairment in cognitive function during mid- to late-adult life. Brains from AD patients show several distinct neuropathological features, including extracellular β -amyloid-containing plaques, intracellular neurofibrillary tangles composed of abnormally phosphorylated τ , and degeneration of cholinergic neurons of the basal forebrain. In this review, we will present evidence implicating involvement of the basal forebrain cholinergic system in AD pathogenesis and its accompanying cognitive deficits. We will initially discuss recent results indicating a link between cholinergic mechanisms and the pathogenic events that characterize AD, notably amyloid- β peptides. Following this, animal models of dementia will be discussed in light of the relationship between basal forebrain cholinergic hypofunction and cognitive impairments in AD.

Finally, past, present, and future treatment strategies aimed at alleviating the cognitive symptomatology of AD by improving basal forebrain cholinergic function will be addressed. .COPYRG. 2002 Elsevier Science Ltd. All rights reserved.

L5 ANSWER 16 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2002200626 EMBASE
TITLE: Down syndrome and dementia.
AUTHOR: Pary R.J.
CORPORATE SOURCE: Dr. R.J. Pary, Department of Psychiatry, Southern Illinois University, School of Medicine, PO Box 19642, Springfield, IL 62794-9642, United States
SOURCE: Mental Health Aspects of Developmental Disabilities, (2002) Vol. 5, No. 2, pp. 57-63. .
Refs: 35
ISSN: 1057-3291 CODEN: MHADFR
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 008 Neurology and Neurosurgery
038 Adverse Reactions Titles
032 Psychiatry
037 Drug Literature Index
030 Pharmacology
022 Human Genetics
036 Health Policy, Economics and Management
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20 Jun 2002
Last Updated on STN: 20 Jun 2002

AB This article reviews the advances in the evaluation and management of dementia in persons with Down syndrome. It is not inevitable that all older persons with Down syndrome will develop dementia. One of the major changes has been in the evaluation of dementia-like syndrome. This article will review laboratory tests as well as dementia scales, neuropsychological batteries and standardized mental status evaluations. Pharmacological management is also discussed. Lastly, there is a need for expert consensus on clinical guidelines for the evaluation and management of dementia in persons with Down syndrome.

L5 ANSWER 17 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001434139 EMBASE
TITLE: NICE: Faster access to modern treatments? Analysis of guidance on health technologies.
AUTHOR: Raftery J.
CORPORATE SOURCE: Prof. J. Raftery, Health Services Management Centre, School of Public Policy, University of Birmingham, Birmingham B15 2RT, United Kingdom. J.P.Raftery@bham.ac.uk
SOURCE: British Medical Journal, (1 Dec 2001) Vol. 323, No. 7324, pp. 1300-1303. .
Refs: 12
ISSN: 0959-8146 CODEN: BMJOAE
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology
036 Health Policy, Economics and Management
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Jan 2002
Last Updated on STN: 3 Jan 2002

L5 ANSWER 18 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001395243 EMBASE

TITLE: A NICE job and somebody's got to do it.
 SOURCE: Pharmaceutical Journal, (27 Oct 2001) Vol. 267, No. 7171,
 pp. 591-592. .
 ISSN: 0031-6873 CODEN: PHJOAV
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; Note
 FILE SEGMENT: 006 Internal Medicine
 010 Obstetrics and Gynecology
 016 Cancer
 017 Public Health, Social Medicine and Epidemiology
 036 Health Policy, Economics and Management
 037 Drug Literature Index
 LANGUAGE: English
 ENTRY DATE: Entered STN: 26 Nov 2001
 Last Updated on STN: 26 Nov 2001

L5 ANSWER 19 OF 19 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights
 reserved on STN

ACCESSION NUMBER: 2000356700 EMBASE
 TITLE: Therapeutic agents for attention deficit
 disorders.
 AUTHOR: Howard H.R.
 CORPORATE SOURCE: H.R. Howard, Department of Neurosciences, Pfizer Global
 Research Division, Pfizer Inc., Groton, CT 06340, United
 States
 SOURCE: Expert Opinion on Therapeutic Patents, (2000) Vol. 10, No.
 10, pp. 1549-1559. .
 Refs: 38
 ISSN: 1354-3776 CODEN: EOTPEG
 COUNTRY: United Kingdom
 DOCUMENT TYPE: Journal; General Review
 FILE SEGMENT: 007 Pediatrics and Pediatric Surgery
 030 Pharmacology
 032 Psychiatry
 037 Drug Literature Index
 038 Adverse Reactions Titles
 LANGUAGE: English
 SUMMARY LANGUAGE: English
 ENTRY DATE: Entered STN: 26 Oct 2000
 Last Updated on STN: 26 Oct 2000

AB Attention deficit hyperactivity disorder (ADHD) is a syndrome that affects
 young children, manifesting itself through inappropriate behaviours and
 learning difficulties and persisting in many instances into adulthood.
 Treatment with stimulants, such as methylphenidate, is often sufficient
 but carries with it some risk for the emergence of unwanted side effects
 that can influence compliance, particularly with children. Newer agents
 and novel mechanisms for achieving control of the symptoms associated with
 ADHD are proposed in recent patents and applications and are presented in
 this review.

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
75.82	76.03

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-8.58	-8.58

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:02:56 ON 21 SEP 2007